<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195139</url>
  </required_header>
  <id_info>
    <org_study_id>COGNO 16/01, CTC 0156</org_study_id>
    <secondary_id>ACTRN12617000267358</secondary_id>
    <nct_id>NCT04195139</nct_id>
  </id_info>
  <brief_title>Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM</brief_title>
  <acronym>NUTMEG</acronym>
  <official_title>A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cooperative Trials Group for Neuro-Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on
      overall survival in newly diagnosed elderly patients with glioblastoma.

      Who is it for? You may be eligible to join this study if you are aged 65 years or above, with
      newly diagnosed histologically confirmed GBM (WHO grade IV glioma including gliosarcoma)
      following surgery.

      The study aims to evaluate whether the combination of adjuvant nivolumab with temozolomide
      improves overall survival outcomes for this patient population. The outcome of the study will
      help determine the most effective treatment for patients with glioblastoma in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study details:

      Participants will be allocated to either experimental or control group in a 2:1 ratio by
      chance (randomly). Patients assigned to the experimental group will receive a course of
      nivolumab via intravenous infusion (240 mg on days 1 and 15 every 28 days for cycles 1-4;
      then 480 mg day 1 every 28 days for cycles 5-6) in addition to the standard regimen of
      Temozolomide (TMZ) tablets and radiotherapy. Patients assigned to the control group will
      receive the standard treatment of adjuvant temozolomide (150-200mg/m2 days 1-5 every 28 days)
      for 6 cycles and standard radiotherapy treatment (40 Gy administered in 15 fractions).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will receive radiotherapy (weekdays over 21 days) concurrently with temozolomide (TMZ) tablets 75mg/m2 daily for 21 days.
After a 4 week break, participants will receive either experimental or standard treatment.
Experimental treatment: Participants assigned to this group will receive nivolumab intravenous infusions (days 1 and 15 every 28 days with concurrent adjuvant temozolomide tablets days 1-5, every 28 days) for 6 cycles.
Standard treatment: Participants assigned to this group will receive the standard treatment of adjuvant temozolomide (days 1-5 every 28 days) for 6 cycles.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival outcomes</measure>
    <time_frame>24 months post randomisation of first participant</time_frame>
    <description>Overall survival is defined as the interval from the date of randomisation to date of death from any cause, or date of last known follow-up alive. This will be calculated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months post randomisation</time_frame>
    <description>Progression free survival (PFS) is defined as the interval from date of randomisation to the date of first evidence of disease progression or death from any cause, whichever occurs first. The PFS will be calculated using the Kaplan-Meier method and disease progression is defined according to modified Response Assessment in Neuro-Oncology (RANO) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>The NCI Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) will be used to classify and grade the intensity of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life of participants</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>Health related quality of life will be reported directly by the participants using the EORTC core quality of life questionnaire QLQ C-30. The QLQ-C30 is a 30-item questionnaire with 5 functional scales (physical, role, cognitive, emotional, and social), global health status, 3 symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; higher score=better level of physical functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life of participants</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>Health related quality of life will be reported directly by the participants using the EORTC core quality of life questionnaire brain cancer specific module (QLQ-BN20). The QLQ-BN20 consisted of 20 items assessing visual disorders, motor dysfunction, communication deficit, various disease symptoms (e.g. headaches and seizures), treatment toxicities (e.g. hair loss) and future uncertainty. All of the 20 items are rated on a 4 point scale (1=not at all, 4=very much), and were linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life of participants</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>Health related quality of life will be reported directly by the participants using the EORTC core quality of life questionnaire EuroQol EQ-5D-5L. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and as overall health using a &quot;thermometer&quot; visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic function of participants</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>Cognitive function will be assessed by the Neurologic Assessment in Neuro-Oncology (NANO) scales. The NANO is a quantifiable evaluation of nine major domains for subjects with brain tumours. The domains include: gait, strength, ataxia, sensation, visual field, facial strength, language, level of consciousness, behaviour and overall. Each domain is rated on a scale of 0 to 3 where 0 represents normal and 3 represents the worst severity. The evaluation is based on direct observation/testing performed during routine office visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlating modified RANO and immune related RANO in the experimental arm</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>Site investigators will assess disease progression using modified RANO criteria for clinical decision making. The study team will coordinate image analysis and central review of MRI including modified RANO (both experimental and comparator arms) and iRANO (in the experimental arm).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Nivolumab and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After radiotherapy and 4 week break, participants who are assigned to this arm will receive Nivolumab with concurrent adjuvant temozolomide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After radiotherapy and 4 week break, participants who are assigned to this arm will receive the standard treatment of adjuvant temozolomide treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).</description>
    <arm_group_label>Nivolumab and Temozolomide</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.</description>
    <arm_group_label>Nivolumab and Temozolomide</arm_group_label>
    <arm_group_label>Temozolomide</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temcad</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults, aged greater than or equal to 70 years, or aged 65-69 years if long course RT
             is inappropriate, with newly diagnosed histologically confirmed GBM (WHO grade IV
             glioma including gliosarcoma) following surgery

          2. Tissue available for MGMT testing

          3. ECOG 0-2

          4. Life expectancy of &gt;12 weeks

          5. Adequate bone marrow function (platelets &gt; 100 x 10^9/L, ANC &gt; 1.5 x 10^9/L)

          6. Adequate liver function (ALT/AST &lt; 1.5 x ULN)

          7. Adequate renal function (creatinine clearance &gt; 30 ml/min measured using
             Cockroft-Gault

          8. Willing and able to comply with all study requirements, including treatment, timing
             and/or nature of required assessments including MRI

          9. Signed, written informed consent

        Exclusion Criteria:

          1. Specific comorbidities or conditions (e.g. psychiatric) or concomitant medications
             which may impact with the administration of study related treatments or procedures

          2. Other co-morbidities or conditions that may compromise assessment of key outcomes

          3. Prior chemotherapy or cranial radiation within the last 5 years. Prior or concomitant
             therapies for GBM (except surgery).

          4. History of another malignancy within 2 years prior to registration. Patients with a
             past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the
             skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma
             of the bladder are eligible. Patients with a history of other malignancies are
             eligible if they have been continuously disease free for at least 2 years after
             definitive primary treatment.

          5. Significant infection, including chronic active hepatitis B, hepatitis C, or HIV.
             Testing for these is not mandatory unless clinically indicated

          6. Active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus,
             hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo,
             psoriasis or alopecia) not requiring systemic treatment, or conditions not expected to
             recur in the absence of an external trigger are permitted to enroll.

          7. A condition other than GBM, requiring systemic treatment with either corticosteroids
             (&gt; 10 mg daily prednisone or equivalent) or other immunosuppressive medications within
             14 days prior to randomisation. Inhaled or topical steroids, and adrenal replacement
             steroid doses &gt; 10 mg daily prednisone or equivalent, are permitted in the absence of
             active autoimmune disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>NUTMEG Project Manager</last_name>
    <phone>+61 2 9562 5000</phone>
    <email>nutmeg@ctc.usyd.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret Johnson, Principal Investigator</last_name>
      <phone>+ 919 684 5301</phone>
      <email>margaret.o.johnson@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Campbelltown Hospital</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Tognela, Principal Investigator</last_name>
      <phone>+61 2 4634 4355</phone>
      <email>Annette.Tognela@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao-Wen Sim, Principal Investigator</last_name>
      <phone>+61 2 8514 0605</phone>
      <email>Hao-Wen.Sim@lh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wong, Principal Investigator</last_name>
      <phone>+61 2 4320 9813</phone>
      <email>matt.wong@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Gedye, Principal Investigator</last_name>
      <phone>+61 2 4941 8424</phone>
      <email>Craig.Gedye@calvarymater.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Begbie, Principal Investigator</last_name>
      <phone>+61 2 6581 4053</phone>
      <email>stephen.begbie@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Hovey, Principal Investigator</last_name>
      <phone>+61 2 9382 5111</phone>
      <email>Elizabeth.Hovey@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Back, Principal Investigator</last_name>
      <phone>+61 2 9463 1300</phone>
      <email>mback@nsccahs.health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Brungs, Principal Investigator</last_name>
      <phone>+612 4222 5200</phone>
      <email>Daniel.Brungs@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zarnie Lwin, Principal Investigator</last_name>
      <phone>+61 7 3646 7986</phone>
      <email>Zarnie.Lwin@Health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Eliadis, Principal Investigator</last_name>
      <phone>+61 7 3737 4500</phone>
      <email>Paul.Eliadis@iconcancerCentre.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Cuff, Principal Investigator</last_name>
      <phone>+61 7 3636 8111</phone>
      <email>Katharine.Cuff@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hien Le, Principal Investigator</last_name>
      <phone>+61 8 7074 2432</phone>
      <email>hien.le@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganessan Kichenadasse, Principal Investigator</last_name>
      <phone>+61 8 8204 8997</phone>
      <email>Ganessan.kichenadasse@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemary Harrup, Principal Investigator</last_name>
      <phone>+61 3 6166 8308</phone>
      <email>rosemary.harrup@ths.tas.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagun Parakh, Principal Investigator</last_name>
      <phone>+614 36 387 664</phone>
      <email>sagun.parakh@monashhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Gan, Principal Investigator</last_name>
      <phone>+ 61 3 9496 9925</phone>
      <email>Hui.Gan@onjcri.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Field, Principal Investigator</last_name>
      <phone>+61 3 8559 5000</phone>
      <email>Kathryn.field@petermac.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epworth Healthcare</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ross Jennens, Principal Investigator</last_name>
      <phone>+61 3 9069 8282</phone>
      <email>jennens@bigpond.net.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Nowak, Principal Investigator</last_name>
      <phone>+61 8 6457 3841</phone>
      <email>Anna.Nowak@health.wa.gov.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBM</keyword>
  <keyword>Astrocytoma WHO grade IV</keyword>
  <keyword>Elderly</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

